Source: Siyu MedTech; Editor: Sophia
Reprint requirements: Can be reprinted 24 hours after the first publication, source must be credited.
On August 29, 2024, Dr. Sam Ajizian, Chief Medical Officer of Medtronic's Acute Care and Monitoring (ACM), announced on LinkedIn that he would be leaving the company.Samuel Ajizian, M.D., Chief Marketing Officer of Patient Monitoring, Vice President of Global Clinical Research and Medical Science, is also a board-certified pediatric critical care physician with over 20 years of clinical practice experience in the pediatric ICU.He earned his medical degree at the University of Southern California, completed his pediatric residency and served as chief resident at Children's Hospital Los Angeles. He then joined the U.S. Air Force, serving as a pediatrician and flight surgeon in an F-16 squadron.Joined Medtronic in 2015, initially serving as the Vice President of Medical Affairs for the Patient Monitoring and Recovery Business Unit.In 2018, he served asMITG'sThe leader of the Office of Medical Safety. Subsequently, Dr. Ajizian became the interim head of the MITG Scientific Communications team, responsible for overseeing the creation of critical compliance-related deliverables, including Clinical Evaluation Reports.In 2020, Dr. Ajizian served at MedtronicChief Medical Officer of Patient Monitoringand Global Vice President of Clinical Research and Medical Science.# Medtronic's ACM BusinessAs the epidemic situation stabilizes, the demand for ventilators in the market decreases, leading to a decline in the profitability of the ventilator business.On February 20, 2024, Medtronic's global CEO Geoff Martha announced via a conference call: the closure of the ventilator business, and the integration of its remaining patient monitoring and respiratory intervention businesses into the Acute Care & Monitoring (ACM) operating unit, as part of Medtronic's Medical Surgical division.Medtronic Exits Ventilator Production Line, andMerge and reorganize the remaining Patient Monitoring and Respiratory Interventions (PMRI) business into the ACM department.The company will allocate the funds saved from exiting the ventilator business to increase investment in the ACM division, particularly in remote patient monitoring.The ACM department will includePulse Oximeters, Remote Patient Monitoring, Airway Management and Respiratory Monitoring Products, to meet the needs of different patients.In the past few months, several senior executives have left Medtronic.20In June 2024, Karen Parkhill of Medtronic plans to step down from her position as Executive Vice President and Chief Financial Officer (CFO).`, accepting the position of Chief Financial Officer at global tech giant HP.`
June 2024,Medtronic Confirms Rob ten Hoedt, Executive Vice President and President of Global Regions, to RetireThis marks an important change in the company's leadership.
At the same time, Endologix, as a company specializing in the medical device field,Hired two former leaders of Medtronic to join its top management team, serving as Chief Commercial Officer (CCO) and Chief Operating Officer (COO), respectively.In May 2024, Bonnie Handke, a 25-year veteran of Medtronic, moved to CVRx.She serves as the Vice President of Global Health Economics at Medtronic, overseeing policy and reimbursement for coronary and renal denervation, peripheral vascular health, structural heart disease, aortic, and cardiac surgery.In March 2024, Gio Di Napoli, President of Medtronic's Gastrointestinal Business, and Ariel Mactavish, President of the Respiratory Interventions Division, announced their resignations.Christopher Cleary, former Senior Vice President of Corporate Development at Medtronic, also left in March after serving for 10 years.Medtronic Executive Vice President and President of the Medical Surgical Portfolio, Bob White, has also left.
# Conclusion
Medtronic, as a global leading medical technology company, is undergoing a series of significant changes and strategic adjustments to adapt to the ever-changing market environment and the needs for future growth.
Along with the business adjustment, the companyFocus more on business areas with high growth potential and alignment with the company’s strategic direction, and carry out organizational restructuring.Including layoffs and early retirement plans to optimize operational efficiency.
At the same time, the company isImplement stricter cost management measures, to reduce costs and improve financial efficiency. AndIncrease Investment in Automation and Digital Technologies, in order to improve production efficiency, enhance product quality, and accelerate the pace of innovation.
These changes and initiatives demonstrate Medtronic's rapid response to the current market conditions, as well as its proactive positioning for future development opportunities.
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
